Aqueous humor and plasma concentrations of ciprofloxacin and moxifloxacin following topical ocular administration in ophthalmologically normal horses

American Journal of Veterinary Research

Volumn 71, Issue 5, 2010, Pages 564-569

  Clode, Alison B ^a   Davis, Jennifer L ^a   Salmon, Jacklyn ^a   LaFevers, Heath ^a   Gilger, Brian C ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARACENTESIS; PLASMA HALF LIFE; ANIMAL; ANIMAL DISEASE; BLOOD; METABOLISM; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; TOPICAL DRUG ADMINISTRATION;

ANIMALIA; BACTERIA (MICROORGANISMS); EQUIDAE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; CIPROFLOXACIN; FEMALE; HORSES; MALE; ORCHIECTOMY; QUINOLINES;

EID: 77953035334     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.5.564     Document Type: Article

References (35)

1. Andrew S, Willis A. Diseases of the cornea and sclera. In: Gilger B, ed. Equine ophthalmology. St Louis: Elsevier Saunders, 2005;157-251.
2. Ollivier FJ, Brooks DE, Kallberg ME, et al. Evaluation of various compounds to inhibit activity of matrix metalloproteinases in the tear film of horses with ulcerative keratitis. Am J Vet Res 2003;64:1081-1087.
3. Strubbe DT, Brooks DE, Schultz GS, et al. Evaluation of tear film proteinases in horses with ulcerative keratitis. Vet Ophthalmol 2000;3:111-119.
4. Sauer P, Andrew SE, Lassaline M, et al. Changes in antibiotic resistance in equine bacterial ulcerative keratitis (1991-2000): 65 horses. Vet Ophthalmol 2003;6:309-313.
5. Keller RL, Hendrix DV. Bacterial isolates and antimicrobial susceptibilities in equine bacterial ulcerative keratitis (1993-2004). Equine Vet J 2005;37:207-211.
6. Moore CP, Fales WH, Whittington P, et al. Bacterial and fungal isolates from Equidae with ulcerative keratitis. J Am Vet Med Assoc 1983;182:600-603. (Pubitemid 13127440)
7. Regnier A. Clinical pharmacology and therapeutics part 1: drug delivery. In: Gelatt K, ed. Veterinary ophthalmology. 4th ed. Ames, Iowa: Blackwell, 2007;271-287.
8. Clode AB, Davis JL, Salmon J, et al. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Am J Vet Res 2006;67:296-301. (Pubitemid 43285605)
9. Kim DH, Stark WJ, O'Brien TP. Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. Curr Med Res Opin 2005;21:93-94.
10. McCulley J, Caudle D, Aronowicz J, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006;113:955-959. (Pubitemid 43795230)
11. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005;50(suppl 1):S32-S45.
12. Sakamoto H, Sakamoto M, Hata Y, et al. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 2007;17:372-376. (Pubitemid 47056292)
13. Solomon R, Donnenfeld E, Perry H, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112:466-469. (Pubitemid 40312502)
14. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-958.
15. Duggirala A, Joseph J, Sharma S, et al. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol 2007;55:15-19. (Pubitemid 46065927)
16. Afshari NA, Ma JJ, Duncan SM, et al. Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis. J Ocul Pharmacol Ther 2008;24:217-223.
17. Kotlus BS, Wymbs RA, Vellozzi EM, et al. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates. Am J Ophthalmol 2006;142:726-729.
18. Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol 2005;50:S7-S15.
19. Soussy CJ, Nguyen J, Goldstein F, et al. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 2003;9:997-1005.
20. Yagci R, Oflu Y, Dinçel A, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye (Lond) 2007;21:990-994. (Pubitemid 47071612)
21. Michau T. Equine ocular examination: basic and advanced diagnostic techniques. In: Gilger B, ed. Equine ophthalmology. St Louis: Elsevier Saunders, 2005;1-62.
22. Papich MG, Van Camp SD, Cole JA, et al. Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. J Vet Pharmacol Ther 2002;25:343-350.
23. Gardner SY, Davis JL, Jones SL, et al. Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing. J Vet Pharmacol Ther 2004;27:57-60.
24. Thompson A. Ocular toxicity of fluoroquinolones. Clin Experiment Ophthalmol 2007;35:566-577.
25. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205-215. (Pubitemid 33131188)
26. Andrew SE, Ramsey DT, Hauptman JG, et al. Density of corneal endothelial cells and corneal thickness in eyes of euthanatized horses. Am J Vet Res 2001;62:479-482. (Pubitemid 33605768)
27. Edelhauser H, Ubels J. The cornea and the sclera. In: Kaufman P, Alm A, eds. Adler's physiology of the eye. 10th ed. St Louis: Mosby, 2003;47-114.
28. Biros DJ, Brooks DE, Brown MP, et al. Regional and zonal variations in the sulfation patterns of chondroitin sulfate in normal equine corneal stroma. Am J Vet Res 2002;63:143-147.
29. Gilger BC, Reeves KA, Salmon JH. Ocular parameters related to drug delivery in the canine and equine eye: aqueous and vitreous humor volume and scleral surface area and thickness. Vet Ophthalmol 2005;8:265-269.
30. Gum G, Gelatt K, Esson D. Physiology of the eye. In: Gelatt K, ed. Veterinary ophthalmology. Ames, Iowa: Blackwell, 2007;149-182.
31. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-505.
32. Mather R, Karenchak L, Romanowski E, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-466. (Pubitemid 34258055)
33. Schoenwald R. The control of drug bioavailability from ophthalmic dosage forms. In: Smolen V, Ball L, eds. Controlled drug bioavailability. New York: John Wiley & Sons, 1985;257.
34. DeSantis L, Patil P. Pharmacokinetics. In: Mauger T, Craig E, eds. Havener's ocular pharmacology. 6th ed. St Louis: Mosby, 1994;22-52.
35. Weese JS, Kaese HJ, Baird JD, et al. Suspected ciprofloxacin-induced colitis in four horses. Equine Vet Educ 2002;14:182-186.